CureVac’s Final Chapter: Shareholders Seal Merger Fate

A significant deadline has arrived for one of Germany’s most closely watched biotech narratives. The offer period for BioNTech’s exchange tender concludes today, marking the irreversible end of CureVac’s journey as an independent publicly traded entity. For investors still holding shares, this final cutoff carries specific implications, while the path toward an inevitable delisting from public markets is now clear.

The direct consequence for CureVac’s equity is its imminent disappearance from the Nasdaq exchange. Following the approved legal merger, CureVac will effectively be absorbed into a new entity or integrated wholly, allowing BioNTech to consolidate the mRNA technology platform without the operational overhead of a separate listed company. Read more...